|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1996-3-20
|
|
pubmed:abstractText |
LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-1505742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-1592699,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-1624399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-1651826,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2088183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2143434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2149921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2523687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2723455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2793597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2817848,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2891921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2921228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-2948443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-3192496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-8329505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8585753-8407579
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2585-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8585753-Animals,
pubmed-meshheading:8585753-Anti-Bacterial Agents,
pubmed-meshheading:8585753-Drug Resistance, Microbial,
pubmed-meshheading:8585753-Enterococcus,
pubmed-meshheading:8585753-Enterococcus faecalis,
pubmed-meshheading:8585753-Enterococcus faecium,
pubmed-meshheading:8585753-Gram-Positive Bacteria,
pubmed-meshheading:8585753-Gram-Positive Bacterial Infections,
pubmed-meshheading:8585753-Humans,
pubmed-meshheading:8585753-Male,
pubmed-meshheading:8585753-Methicillin Resistance,
pubmed-meshheading:8585753-Mice,
pubmed-meshheading:8585753-Microbial Sensitivity Tests,
pubmed-meshheading:8585753-Rats,
pubmed-meshheading:8585753-Rats, Sprague-Dawley,
pubmed-meshheading:8585753-Staphylococcus,
pubmed-meshheading:8585753-Streptococcus,
pubmed-meshheading:8585753-Vancomycin
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
|
|
pubmed:publicationType |
Journal Article
|
